Most affordable compounded GLP-1 in New York City
⚠ Prototype pricing & New York legal details — verify before publishing.
GLP-1 care in New York City is delivered by telehealth and shipped, so residents access the same national providers. NexLife is the lowest fully-credentialed flat option (sema $145, tirz $186); Embody is the lowest sticker at $99. Largest US city; New York generally expects a synchronous telehealth visit to establish care, and non-resident pharmacies must register.
Lowest-cost providers serving New York City
New York rules that apply in New York City
- PHPharmacy regulatorNew York State Board of Pharmacy — www.op.nysed.gov/professions/pharmacy (verify). Non-resident pharmacies shipping to New York City must be licensed in New York.
- RXTelehealth visitNew York generally expects a live audio-video visit to establish care.
- DBMonitoring programNY PMP (I-STOP).
See the full New York state guide for details.
Lowest fully-credentialed option in New York City
NexLife
★★★★★ Compounded semaglutide + tirzepatide- MD/DO-supervised care
- 503A & 503B pharmacy network
- Labs included
- LegitScript-certified
- NABP-accredited pharmacy partners
- Flat rate, dose-independent
- Third-party batch testing
- Care360 coaching included
Affiliate link. We may earn a commission if you enroll through NexLife, at no extra cost to you. It does not affect this ranking — see how we score providers.
Verify before you buy
Wherever you are in New York City, the 2026 rules are the same: broad compounding ended, and only patient-specific 503A compounding remains. Read the 2026 legal status and run any provider through our verification checklist.
Independent & transparent
This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →